Last reviewed · How we verify

Shandong New Time Pharmaceutical Co., LTD — Portfolio Competitive Intelligence Brief

Shandong New Time Pharmaceutical Co., LTD pipeline: 2 marketed, 0 filed, 3 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 3 Phase 3 4 Phase 2 6 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Huazhi Rougan Granule Placebo granule Huazhi Rougan Granule Placebo granule marketed
Huazhi Rougan granule Huazhi Rougan granule marketed Hepatology / Traditional Chinese Medicine
F027 F027 phase 3 SGLT2 inhibitor SGLT2 Diabetes
Rituxan +CHOP Rituxan +CHOP phase 3 Monoclonal antibody CD20 Oncology
H02+CHOP H02+CHOP phase 3 Polychemotherapy regimen Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. GlaxoSmithKline · 3 shared drug classes
  2. Bayer · 3 shared drug classes
  3. Merck Sharp & Dohme LLC · 3 shared drug classes
  4. HK inno.N Corporation · 2 shared drug classes
  5. CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · 2 shared drug classes
  6. AstraZeneca · 2 shared drug classes
  7. Addpharma Inc. · 2 shared drug classes
  8. Astellas Pharma Inc · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Shandong New Time Pharmaceutical Co., LTD:

Cite this brief

Drug Landscape (2026). Shandong New Time Pharmaceutical Co., LTD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shandong-new-time-pharmaceutical-co-ltd. Accessed 2026-05-16.

Related